1Fuster V, Ryden LE, Asinger RW, et al.ACC/ AHA Practice Guidelines.Circulation, 2001; 104:2118.
2Abdelhafiz AH. A review of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation. Clin Ther, 2001 ; 23 ( 10 ) : 1628 - 1636.
3Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med, 1994; 120:897 - 902.
4Gorter JW. Major bleeding during anticoagulation after cerebral ischemia:patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT) . European Atrial Fibrillation Trial (EAFT) study groups.Neurology,1999; 53: 1319-1327.
5Chenhsu RY, Chiang SC, Chou MH, et al. Long - term treatment with warfarin in Chinese population. Ann Pharmacother, 2000; 34:1395 1401.
6Copland M, Walker ID, Tait RE. Oral anticoagulation and hemorrhagic complication in an elderly population with atrial fibrillation. Arch Inten Med, 2001 ; 161 : 2125 - 2128.
7Beyth BJ, Landefeld CS. Outcomes of warfarin the rapy: lessons from thereal world[Editorial] .Mayo Clin Proc, 1995;70:806-808.
8Saour JN, Sieck JO, Mamo LA, et al. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med, 1990; 322:428 - 432.
9Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a rtmta - analysis. Ann Intern Med, 1999; 131:492 - 501.
10Hansson L, Zanchetti A, Carruthers G, et al. Effects of intensive blood →pressure lowering and low - dose aspirin in patients with hypertension :principal results of the Hypertension Optimal Treatment (HOT) randomiseed tral. lancet. 1998:351:1755 - 1762.
